cyrilzakka/clinical-trials huggingface dataset:
Iron Deficiency Anaemia in Pregnant Patients Presenting for Antenatal Care

This is a cross-sectional, prospective study of iron deficiency anaemia among pregnant patients presenting for antenatal care at a secondary level institution in the Western Cape, Mowbray Maternity Hospital, over a one-week period.


Eligibility Criteria:
Inclusion Criteria:

* All women presenting to the antenatal care services at Mowbray Maternity Hospital over the period of study recruitment.
* ≥ 18 years of age.
* Screen as anaemic (World Health Organisation \<11g/dl) on bedside finger-prick haemoglobin.
* Who consent to participate.

Exclusion Criteria:

Patients who refuse to participate, and those under the age of 18 years will be excluded from the study.
Clinical Study of the Treatment of Chiari Malformation Combined With Type II Skull Base Depression

The research background of this study is that Chiari malformation (CM) is a congenital malformation in the foramen magnum region, often associated with syringomyelia, basilar depression, odontoid dislocation and other craniocervical junction deformities. The traditional surgical method for Chiari malformation with skull basilar depression is simple decompression without fixation, so it cannot effectively maintain the stability of the cervical spine and reduce the compression of the brainstem and cervical cord, often resulting in poor curative effect and aggravated symptoms. The cervical spine is the most flexible and most mobile part of the spine, and the instability of the cervical spine will directly affect the quality of life of patients after surgery. Subsequently, with the continuous advancement of technology and the continuous development and improvement of surgical methods, Investigators can relieve spinal cord compression by using atlanto-occipital decompression and dissection followed by C1/2 lateral arthrolysis combined with occipitocervical fusion. So, is this surgical combination the most effective surgery for patients with Chiari malformation and type II skull basilar depression? How should doctors adjust to the best surgical approach to treat patients with Chiari malformation and type II skull basilar depression? These questions have long puzzled neurosurgeons. By conducting this research, investigators hope that participants can participate in it, and work with them to answer this question, and jointly promote the development and progress of doctors' careers, while benefiting more patients.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Chiari malformation
* Combined with type II skull base depression
* Clinical symptoms related to the disease
* Complete clinical imaging data
* Must be the first surgery

Exclusion Criteria:

* Secondary cerebellar tonsillar hernia
* Severe atlantoaxial dislocation
* Osteochondroplastica
* Rheumatoid arthritis
* Down syndrome
* Refurbished case reoperation
Retrospective Analysis of Surgical Outcomes in Patients Treated for Gunshot-Related Bone Defects at Mekelle University Hospital

his project looks back at past surgeries performed between 2019 and 2023 in a hospital in Mekelle, Ethiopia. During this time, a team of doctors from Austria and other countries visited the hospital to help patients who had been badly injured by gunshots, especially in the legs and arms. These injuries were very serious and often needed complex operations.

Why is this important? Mekelle is in a region that was affected by conflict and war. Hospitals there have very limited resources - not enough electricity, medical tools, or staff. The patients are often young people with injuries that would be easier to treat in better-equipped hospitals. This project wants to understand how the surgeries went under these difficult conditions and what could be done better in the future.

What will the doctors do in this study? They will look at hospital records from about 74 patients who had these surgeries. The doctors will not contact patients or do any new treatments. They are only using data that was already collected during treatment. The names and personal details of patients will not be used - everything will be anonymous.

The doctors will study:

The age and gender of patients What type of surgery was done How long surgeries lasted and whether electricity was available What happened after surgery - for example, whether the wound healed well or if there were problems What is the goal? The goal is to learn what worked well and what didn't - and to use this knowledge to plan future humanitarian missions. The results could also help improve care for people in similar situations in other parts of the world.

Are there any risks? No. This is a purely retrospective study. That means it only looks at past data. There will be no contact with patients, and no further action taken based on the study. All personal information will be protected according to strict privacy rules.

Who is behind this project? The project is led by Dr. Viktoria Koenig, a plastic surgeon from Austria who took part in the missions and has experience with this kind of surgery.

Why is this relevant? This study will help medical teams better prepare for working in difficult environments. It will also show how surgery can still help people even when resources are very limited - and highlight the importance of teamwork, planning, and flexible medical approaches.


Eligibility Criteria:
Inclusion Criteria:

* All patients who underwent pedicled or free tissue transfer during the study period

Exclusion Criteria:

* All other patients
COVID-19 Detection Tests in Different Body Fluids

A clinical and experimental study will be carried out in which the clinician will investigate the PCR of the virus early in different body fluids (blood, semen, urine, saliva) and monitor its experimental clearance and evaluate in vitro diagnostic tests and inhibitory factors of viral proliferation.

The World Health Organization (WHO) declared Coronavirus 2019 (COVID-19) as a pandemic on March 11, 2020. Due to the rapid spread of the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2), we are currently facing an unprecedented global situation. One of the main pillars in the control of an epidemic is the performance of large-scale tests providing a quick and accurate diagnosis so that the authorities can take timely action. Therefore, tests for COVID-19 should be prompt, widely available, and implemented outside the hospital environment, to avoid overloading the health system and decreasing the risks of hospital transmission to other patients and health professionals. Although universal testing is a cornerstone for reducing the burden of COVID-19, the accuracy of the commercially available tests for COVID-19 in Brazil remains uncertain. In addition, the natural history of the disease in the different organs and tissues is not unquestionably known, nor because the virus develops better in some tissues and not others. There are still many unanswered questions regarding COVID-19. allow more accurate knowledge of the natural history of the disease in the timeline taking into account the acute and long-term phases. Several families of viruses can affect the male genitourinary system, as is the case of the Zika (ZKV) and Ebola viruses. There are reports that in young patients infected with ZKV, the virus persists in semen for up to 6 months after the symptomatic condition. The other SARS-CoV-1 itself was detected in human testicles associated with an inflammatory process (orchiepididymitis), suggesting the possibility that these viruses could also be detected in the semen. As SARS-CoV-1 was able to overcome the hemato-gestural barrier and induce severe testicular damage in the previous outbreak, it is possible that men infected with COVID-19 may also have testicular damage. Another question that remains unanswered is whether the coronavirus can remain in the body of people considered recovered from Covid-19 for an indefinite period. It is also unknown whether there are molecules in the body fluids capable of inhibiting viral growth. The expected benefits are related to a better understanding of COVID's natural history19 and which body fluids can contribute to understanding the pathophysiology of the disease. It will be possible to identify the best time and the test with the best accuracy to diagnose the disease. It is our intention to identify substances in body fluids with an antiviral effect

Eligibility Criteria:
Inclusion Criteria:

* Subjects over the age of 18 years
* Agreement with the IC

Exclusion Criteria:

* History of previous prostate surgery or vasectomy
* Inability to assess participation in the study
A Study of TQ-B3525 on Tolerance and Pharmacokinetics

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.


Eligibility Criteria:
Inclusion Criteria:

* Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
* ECOG PS≤1
* Adequate blood cell counts, kidney function and liver function
* Patients should participate in the study voluntarily and sign informed consent

Exclusion Criteria:

* Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
* Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
* Hepatitis B virus patients with active replication (DNA\> 500 cps / mL), hepatitis C
Alexithymia in Ankylosing Spondylitis

The study included 55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects. Demographic data were recorded for 55 AS patients who were subsequently assessed using the BASMI (Bath Ankylosing Spondylitis Metrology Index) in terms of elasticity and spinal mobility as well as the BASFI (Bath Ankylosing Spondylitis Functional Index) to determine functional status, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess the disease activity and the ASQoL (Ankylosing Spondylitis Quality of Life Questionnaire) to evaluate quality of life. The Toronto Alexithymia Scale-20 (TAS-20) was used for assessment of alexithymia and Beck's Depression Inventory (BDI) for depression among patients.

The study included 55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects. Demographic data were recorded for 55 AS patients who were subsequently assessed using the BASMI (Bath Ankylosing Spondylitis Metrology Index) in terms of elasticity and spinal mobility as well as the BASFI (Bath Ankylosing Spondylitis Functional Index) to determine functional status, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess the disease activity and the ASQoL (Ankylosing Spondylitis Quality of Life Questionnaire) to evaluate quality of life. The Toronto Alexithymia Scale-20 (TAS-20) was used for assessment of alexithymia and Beck's Depression Inventory (BDI) for depression among patients.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed as AS for at least 1 year according to the ASAS classification criteria
* over 18 years old

Exclusion Criteria:

* fibromyalgia
* age less than 18 years
* vision and hearing impairment
* neurological disease (Parkinson's disease, multiple sclerosis, cerebrovascular disease),
* history of a psychiatric disorder (schizophrenia, bipolar disorder)
* history of chronic condition (DM, thyroid disease) or malignancy
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of glaucoma or ocular hypertension

Exclusion Criteria:

* Active ocular disease other than glaucoma or ocular hypertension
* Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)
Prospective Electronic Polygenic Risk Study - Second Phase

This study will investigate the role of polygenic risk scores (PRS) in preventive health.

This study will investigate the role of polygenic risk scores (PRS) in preventive health. Specifically, the purpose of this study is to determine whether knowledge of the degree of coronary artery disease (CAD) genetic risk or glaucoma genetic risk, as measured and conveyed by a PRS, influences patient and physician decision-making as well as clinical outcomes during short-term (6-month / 2-year) and long-term (3-year / 5-year) follow-up. A CAD and glaucoma PRS will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS. This study design allows for causal attribution of preventive actions and clinical outcomes to the receipt and degree of genetic risk. The design is informed by a pilot (MyGeneRank) and phase 1 (PEPRS first phase) study, with the key extensions being the addition of randomization and increasing the study population size to power causal association with long-term, hard clinical outcomes.

Eligibility Criteria:
Inclusion Criteria:

* 45 ≥ Age \< 65
* ASCVD Risk Score \> 7.5% as defined by the standard pooled cohort equation
* Access to and ability to use a smartphone

Exclusion Criteria:

* Prior diagnosis of coronary disease as defined by prior myocardial infarction (STEMI or NSTEMI), or revascularization (stent or coronary artery bypass grafting)
* Prior diagnosis or treatment of glaucoma
* Cerebrovascular disease with history of ischemic stroke, TIA, carotid endarterectomy, carotid artery stenting
* Peripheral arterial disease with history of claudication, revascularization (stents or bypass)
* Current and active high-intensity statin prescription (rosuvastatin 20 mg, rosuvastatin 40 mg, atorvastatin 40 mg and atorvastatin 80 mg)
* Anti-PCSK9 therapy
* Lipid apheresis therapy
* Currently enrolled in a clinical trial for lipid lowering therapy
* Known statin intolerance to 2 or more statins in the past
Multicomponent Therapy With Telerehabilitation

In this prospective, randomized study, our aim was to evaluate the comprehensive multicomponent treatment of fibromyalgia women with telerehabilitation, including "patient education, special psychotherapy/psychosocial intervention, and exercise including relaxation exercises". Does it differ in terms of reduction and functionality?

Patients who meet the inclusion criteria will be randomized into two groups by computer program after being numbered according to the order of application. 33 patients in the multicomponent treatment group selected to group 1 (G1) will be treated with telerehabilitation for a total of 6 sessions of two hours once a week for 3 weeks. After 1 month, one more session will be applied for a two-hour follow-up and sustainability. As a control group, 33 patients selected to Group 2 (G2) will be given exercise and training with telerehabilitation.

Patients to whom a multicomponent treatment program will be applied will be included in the program in groups of 10. The presentations will be prepared as power-point presentations and will be presented to the patients online with telerehabilitation.

Interventions to be applied in the multicomponent treatment protocol:

1. Patient education
2. Exercise training
3. Private Psychotherapy
4. Relaxation

Eligibility Criteria:
Inclusion Criteria:

1. Women
2. Symptom persistence for more than 3 months
3. Pervasive Network Scale Score \>7 and Symptom Severity Score \>5 according to 2016 ACR criteria
4. Symptom Severity Score of \>9 and Diffuse Pain Scale Score between 4-6 according to 2016 ACR criteria
5. Getting a high (11 and above) score on the Hospital Anxiety and Depression Scale
6. Having the opportunity to participate in the applications online
7. No change in the medical treatment he received for fibromyalgia syndrome during the study period
8. Those between the ages of 18-55

Exclusion Criteria:

1. Patients with endocrine, neuromuscular, infectious and inflammatory rheumatological diseases
2. Patients with liver or kidney disease
3. Patients with malignancy
4. Patients with a history of severe trauma
5. Patients with severe psychiatric illness
6. Patients with serious physical comorbidities
7. The illiterate
8. Known central nervous system or peripheral nervous system disease, progressive neurological deficit
9. Peripheral venous insufficiency, coagulopathies and anticoagulant drug use
10. Serious cardiovascular pathologies
11. Loss of sensation, loss of position sense, unhealed fracture or open surgical wound
12. Pregnancy
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent
2. Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)

Exclusion Criteria:

1. History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
2. Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
3. Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent
4. Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent
5. Has received any conventional therapeutic agent within 1 months of the first administration of study agent
6. Has received any topic therapeutic agent within 2 weeks of the first administration of study agent
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

The primary objective of this study is to evaluate the effect of GS-9876 versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) in participants with active RA as measured by change from baseline in Disease Activity Score for 28 joint count using C-reactive protein (CRP) (DAS28 (CRP)) at Week 12.


Eligibility Criteria:
Key Inclusion Criteria:

* Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1
* Inadequate response to treatment with oral or parenteral methotrexate (MTX) 7.5 to 25 mg/week continuously for at least 12 weeks
* No evidence of active or latent tuberculosis

Key Exclusion Criteria:

* Prior treatment with B-cell depleting agents (eg, rituximab), unless more than 6 months prior to the first dose of study drug and documented return of CD19+ cells at screening
* Prior treatment with any commercially available or investigational spleen tyrosine kinase (SYK) inhibitor
* Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate wash out as defined in the protocol)
* Concurrent treatment with any biological disease modifying anti-rheumatic drug (bDMARD)(prior bDMARD treatment allowed if appropriate wash out as defined in the protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy

In some patients, levothyroxine liquid gel capsules may demonstrate superior absorption than the tablet option. Impaired absorption of thyroid hormone directly correlates to higher and more unpredictable TSH (thyroid stimulating hormone) levels.

The investigators therefore hypothesize that following thyroidectomy for Stage I/II differentiated thyroid cancer the gel capsule levothyroxine formulation will provide more predictable TSH results and in turn require fewer dose adjustments to achieve optimal hormone levels in the postoperative period.

The aim of this investigation is to compare the use of levothyroxine in liquid gel capsules to tablet form for TSH suppression following thyroidectomy for presumed stage I/II differentiated thyroid cancer.

Ten patients will be randomized prior to surgery to receive levothyroxine in tablet form and ten patients will be randomized to receive in gel capsule form. Both forms will be encapsulated in order to allow double-blinding of the study.

The postoperative goal TSH will be between 0.1 and 0.5 mU/L (milli units per litre) in both arms.

Patients will be seen at weeks 6, 12 and 18 postoperatively and have TSH and Free T4 measured. The primary outcome is the number of patients at each visit that are at goal range TSH.

A secondary analysis will compare the dose changes required between the two groups in order to achieve goal TSH.

Another secondary analysis will investigate the patients' quality of life. Two different surveys (see secondary outcomes below) will be performed at both study entry and completion to compare the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Presumed AJCC (American Joint Committee on Cancer) tumor Stage I or II
* Planned total or near-total thyroidectomy
* Planned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperatively
* Normal serum TSH within 12 months preceding surgery

Exclusion Criteria:

* AJCC Stage III or greater
* Undifferentiated, Anaplastic or Medullary Thyroid Cancer
* Planned postoperative TSH goal other than 0.1-0.5 mU/L
* History of gastrointestinal malabsorption or gastric bypass surgery
* Pregnancy
* Use of medications that alter the absorption or metabolism of levothyroxine
* Prior use of levothyroxine
Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy

The purpose of this study is to compare the number of lymph nodes retrieved with or without the use of intraoperative fluorescence lymphography in laparoscopic radical resection of rectal cancer.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed diagnosis of rectal carcinoma.
* Without multiple primary cancer.
* Without receiving neoadjuvant chemoradiotherapy.
* Sufficient organ function.
* Able to provide written informed consent.

Exclusion Criteria:

* Younger than 18 years or older than 75 years
* Synchronous or metachronous malignancy within 5 years.
* Patients with Intestinal obstruction or perforation or bleeding who require emergency surgery.
* Patients with a history of pelvic irradiation.
* ASA (American Society of Anesthesiologists) grade IV or V.
* Women who are pregnant (confirmed by serum β-Human Chorionic Gonadotropin in women of reproductive age) or breast feeding.
* Severe mental illness.
* Patients with severe emphysema, interstitial pneumonia, or ischemic heart disease who can not tolerate surgery.
* Patients who received steroid therapy within one month.
* Patients or family members misunderstand the conditions and goals of this study.